24-05-2017
INGELHEIM, Germany, May 2017 — Boehringer Ingelheim Animal Health has expanded its suite of innovative biosecurity resources to help swine farms control the introduction and spread of Porcine Reproductive and Respiratory Syndrome (PRRS). The company’s new Comprehensive Online Management Biosecurity Assessment Tool (COMBAT) is now available globally to strengthen the identification and resolution of potential biosecurity hazards as part of a 5-step PRRS control program risk management process.
Successful PRRS control incorporates measures to reduce both existing PRRS virus spread and new virus introduction. The online COMBAT solution facilitates improved biosecurity, pig flow and management practices by assessing the most important risk areas related to PRRS incidence.
“By efficiently helping swine farms identify their most vulnerable areas of risk in the control of PRRS, they can implement corrective biosecurity actions,” said Poul Henning Rathkjen, Sr. Global Technical Manager PRRS. “As the leader in swine health worldwide, we are committed to offering a range of solutions, such as COMBAT, to help protect against PRRS and other challenging swine diseases.”
Using the COMBAT app or website, customers complete a detailed set of questions within four risk categories: internal, external, location and management/pig flow. The farm’s various risks are calculated based on published literature and previous on-farm assessments. The data, presented in a chart that indicates the range and prominence of various risks, can be mapped against risk data from other farms worldwide. The risk assessment results enable producers to discuss, prioritize and guide future risk improvement efforts.
About Boehringer Ingelheim Animal Health
As the second largest animal health business in the world, Boehringer Ingelheim is committed to improving animal health. With more than 10,000 employees worldwide, Boehringer Ingelheim Animal Health has products available in more than 150 markets and a global presence in 99 countries. For more information about Boehringer Ingelheim Animal Health, click here.
Boehringer Ingelheim
Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales.
Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects such as the “Making More Health” initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees’ different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does.
More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.
